Arunjyoti Bio Ventures Ltd. Announces Name Change and Board Decisions Following Q2 Financial Review

Arunjyoti Bio Ventures Ltd. Announces Name Change and Board Decisions Following Q2 Financial Review​

Arunjyoti Bio Ventures Limited concluded a board meeting on July 9, 2026, which covered significant corporate changes, including a proposed name change, audit firm transition, and the review of its unaudited financial results for the quarter ended June 30, 2026.

The Board approved several material decisions regarding the company's structure and governance. A key proposal is the change of the company's name from 'Arunjyoti Bio Ventures Limited' to 'Pasura Industries Limited,' subject to member approval through consequent alterations of the Articles of Association and Memorandum of Association.

In terms of statutory audits, the meeting addressed the resignation of M/s Manoj Parakh & Associates as Secretarial Auditor, effective July 9, 2026. The company subsequently appointed M/s Vivek Surana & Associates, a practicing firm based in Hyderabad, to serve as secretarial auditors. This appointment is temporary, running until the next Annual General Meeting and for a period of five years, covering financial years from 2026-27 to 2030-31, pending shareholder approval.

Financial Performance and Key Takeaways​

The unaudited financial results for the quarter ended June 30, 2026, indicated that Total Income stood at 822.06 Lakhs, against total expenses of 740.22 Lakhs. This resulted in a net profit before tax of 81.84 Lakhs, and a total comprehensive income for the period of 6,124 Lakhs.

The company also confirmed that M/s Manoj Parakh & Associates’ resignation was due to pre-occupation with other professional assignments. Meanwhile, the appointment of M/s Vivek Surana & Associates aligns with their profile as a firm based in Hyderabad with over a decade of experience providing secretarial and advisory services.

A significant managerial decision made during the meeting was the waiver of recovery of excess managerial remuneration amounting to Rs. 25.19 Lakhs, which had been paid to Mr. Pabbathi Badhri Narayana Murthy (Whole-time Director) and Mr. Nadimpalli Vishal (Whole-time Director and CFO) for the Financial Year 2025-26.

Remuneration Revisions and Future Outlook​

The Board also reviewed and revised the remuneration structures for three directors:

• Mr. Pabbathi Badhri Narayana Murthy, Whole-time Director, whose remuneration was revised to Rs. 8,00,000 per month plus a Leave Travel allowance of up to Rs. 10,00,000 per annum.
• Mr. Nadimpalli Vishal, Whole-time Director and CFO, who is entitled to a remuneration of Rs. 5,00,000 per month along with a Leave Travel allowance of up to Rs. 10,00,000 per annum.
• Mr. Pabbathi Dathvik, Whole-time Director, whose revised monthly remuneration is set at Rs. 5,00,000, plus a Leave Travel allowance of up to Rs. 10,00,000 per annum.

The company has also scheduled its Annual General Meeting (AGM) for August 12, 2026, which will be held via video conference or other audio-visual means (OAVM).

Financial Summary Comparison (Amounts in INR Lakhs unless stated otherwise)​

The financial performance data provided by the company can be summarized as follows:


The results were reviewed by the Audit Committee and approved by the Board of Directors during their meeting on July 9, 2026. An independent review was conducted by the auditors to provide moderate assurance regarding the interim financial information.

Stock Price Movement​

Arunjyoti Bio Ventures Ltd shares settled on Thursday at ₹5.82, climbing 1.39% in the post-market session. The stock traded within an intraday range, testing a low of ₹5.62 and peaking at a high of ₹5.90.